Beyond Type 1’s Post

Lexicon Pharmaceuticals, Inc. is forging ahead with renewed determination in its pursuit of FDA approval for sotagliflozin, a groundbreaking therapy for Type 1 diabetes. 💉🩸 Despite facing initial setbacks, recent regulatory insights have sparked new hope, prompting plans for a resubmission of the application by mid-year. CEO Lonnel Coats reaffirms Lexicon's unwavering commitment to advancing sotagliflozin as a potential breakthrough therapy. 💪 If approved, sotagliflozin, proposed under the brand name Zynquista, could complement insulin therapy in adults with Type 1 diabetes mellitus and chronic kidney disease, offering a promising new avenue for managing this complex condition. #LexiconPharmaceuticals #Type1Diabetes #Sotagliflozin #Zynquista #MedicalInnovation #HealthcareAdvancement

NEWS: Improved outcomes for COPD patients in #GreaterManchester through innovative lung health reviews. Health Innovation Manchester and pharmaceutical industry company GSK have collaborated on a Joint-Working project, to optimise the care for people living with #COPD in Greater Manchester. The project has helped to identify patients that may benefit from a review of their lung health and gain additional support in guiding their treatment and management of their COPD. 🔗 Read about the impact here: https://bit.ly/3ZrQomX #weareHInM

Lansoprazole by Murli Krishna Pharma is a medication used to treat indigestion, heartburn, acid reflux and gastroesophageal reflux disease (GERD) in the stomach. Murli Krishna Pharma Pvt. Ltd produces Lansoprazole Micro-Pellets, Lansoprazole EC Pellets, and Lansoprazole Enteric Coated Micro pellets. 🍀 Lansoprazole is used to treat duodenal and gastric ulcers, erosive esophagitis, and gastroesophageal reflux disease (GERD).  🍀It is also used to treat Zollinger-Ellison syndrome, a condition where the stomach produces too much acid. Lansoprazole belongs to a class of drugs known as proton pump inhibitors (PPIs) and works by decreasing the amount of acid produced by the stomach. It is available both over-the-counter and with a prescription. For More information visit: https://lnkd.in/dAqax9yM ---- #Lansoprazole #GastricUlcers #AcidReflux #StomachHealth #GastricHealth #DigestiveHealth #LansoprazoleMedication #AcidReduction #GastrointestinalHealth #LansoprazoleTreatment #Pharmaceuticals #MurliKrishnaPharma #Healthcare #Wellness #LansoprazoleTherapy #PrescriptionMeds #OverTheCounterOptions

Today is World Asthma Day ⚕️ Through products like Zephex® 152a, a low carbon medical propellant that plays a vital role in metered dose inhalers, Koura contributes to the treatment of respiratory disorders like asthma and COPD. In the last decade, over 6 billion pMDIs containing Zephex medical propellants have been produced and used by those with respiratory illnesses. Explore the infographic below to learn how Koura propellants shape the pharmaceutical industry. Are you joining our #pharmaceuticals team this week at #RDD2024 in Tucson? Come see us! #WeAreOrbia #OrbiaFluorandEnergyMaterials

Understanding Ketorolac Tromethamine: A Potent Non-Steroidal Anti-Inflammatory Drug (NSAID) Ketorolac tromethamine is a powerful NSAID commonly used for the short-term management of moderate to severe pain. It works by inhibiting the production of prostaglandins, compounds in the body responsible for inflammation and pain. Clinically, it's valued for its ability to provide strong pain relief comparable to opioids, but without the risk of dependency. However, due to its potential for serious side effects, including gastrointestinal bleeding and renal impairment, its use is typically limited to a maximum of 5 days. As healthcare professionals, it's crucial to balance its benefits and risks to optimize patient care. #Pharmaceuticals #PainManagement #Healthcare #NSAID #KetorolacTromethamine

Discover how the Ceramide Test can reveal crucial insights into your heart health in the 57th issue of the IPA-CPD E-times by Dr. Satyavardhan Rao Nittu, PharmD Learn how elevated ceramide levels can signal increased risk for cardiovascular disease. To read the complete magazine, check out: https://rb.gy/s4pnh8 || Indian Pharmaceutical Association || Manjiri Gharat || Raj Vaidya || #IPA #IPACPD #CPD_Etimes #HeartHealth #CeramideTest

Exciting news for Aussies! Starting March 1st, 2024, the Pharmaceutical Benefits Scheme (PBS) is expanding its range of medicines available on 60-day prescriptions! This means you can now get twice the amount of your medication with just one prescription, leading to significant cost savings. Managing chronic pain conditions like migraines, autoimmune diseases (Crohn's, Ulcerative Colitis, Rheumatoid Arthritis), and trigeminal neuralgia just got more affordable. Talk to your healthcare provider to see if this new cost-saving option is right for you! #PBS #ChronicPain #AffordableHealthcare #affordablemedicine

For decades, the idea of disease-modifying therapies for type 1 diabetes remained a dream for patients and practitioners. Now, that dream has become a reality and additional agents are also showing promise. In the latest #DiabetesDialogue, hosts Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES and Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCES discuss recent data from JDRF International examining use of baricitinib (Olumiant; Eli Lilly and Company) in type 1 diabetes and offer their perspective on the potential of this new era of disease-modifying agents, such as teplizumab (Tzield; Sanofi) and VX-880 (Vertex Pharmaceuticals), in #T1D. https://lnkd.in/eeYffzGX

Transthyretin (trans-thy-re-tin) amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed and potentially fatal disease of the heart muscle. In ATTR-CM, a protein called transthyretin that normally circulates in the bloodstream becomes misshapen and builds up in the heart, nerves and other organs. When these amyloid deposits build up in the heart, the walls can become stiff, making the left ventricle unable to properly relax and fill with blood – called cardiomyopathy. As the condition progresses, the heart can become unable to adequately squeeze to pump blood out of the heart, ultimately leading to heart failure. There are several promising new therapies for ATTR-CM on the horizon or available, so it is important to talk to your health care professionals about treatment options. #Menagen #pharma #pharmaceutical #ATTRCM #HeartAwareness #RareDisease

Alembic Pharmaceuticals Ltd. has received tentative USFDA approval for its generic Selexipag injection, used to treat pulmonary arterial hypertension (PAH). This ANDA is equivalent to Uptravi for Injection and could grant Alembic 180 days of generic marketing exclusivity in the US. PAH is a rare disorder characterized by high blood pressure in the lungs. #AlembicPharma, #USFDAApproval, #Selexipag, #GenericDrugs, #PharmaceuticalNews, #Healthcare, #MedicalResearch, #PAH, #PulmonaryHypertension, #DrugApproval, #PharmaIndustry